(Q48632087)

13 February 2018

title

Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs. (English)

1 reference

13 February 2018

author

Gilberto de Nucci

4

1 reference

13 February 2018

Edson Antunes

object named as

Edson Antunes

5

0 references

author name string

Cristiane F Freitas

1

1 reference

13 February 2018

Rafael P Morganti

2

1 reference

13 February 2018

Joyce M Annichino-Bizzacchi

3

1 reference

13 February 2018

publication date

1 January 2007

1 reference

13 February 2018

Clinical and Experimental Pharmacology and Physiology

published in

1 reference

13 February 2018

volume

34

1 reference

13 February 2018

issue

1-2

1 reference

13 February 2018

page(s)

10-14

1 reference

13 February 2018

Soluble guanylate cyclase: the forgotten sibling.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

NO-independent regulatory site on soluble guanylate cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

NO-independent stimulators of soluble guanylate cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

Role of endothelin-1 and thromboxane A2 in the pulmonary hypertension induced by heparin-protamine interaction in anesthetized dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

Endothelin receptor antagonists in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

The effect of sildenafil on pulmonary embolism-induced oxidative stress and pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

Inhaled nitric oxide in cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

Current treatment strategies for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2007.04524.X

10.1111/J.1440-1681.2007.04524.X

21 January 2018

Identifiers

DOI

1 reference

13 February 2018

PubMed ID

17201729

1 reference

13 February 2018